Association between the paraoxonase-1 192Q>R allelic variant and coronary endothelial dysfunction in patients with early coronary artery disease

Mayo Clinic Proceedings

Volumn 83, Issue 2, 2008, Pages 158-164

  Lavi, Shahar ^a   McConnell, Joseph P ^a   Lavi, Ronit ^a   Barsness, Gregory W ^a   Rihal, Charanjit S ^a   Novak, Gregory D ^a,b   Lerman, Lilach O ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ARYLDIALKYLPHOSPHATASE 1; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ALLELE; ARTERY DIAMETER; ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; EPICARDIUM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS;

EID: 39749174492     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.2.158     Document Type: Article

References (51)

1. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111(3):363-368.
2. Kuvin JT, Karas RH. Clinical utility of endothelial function testing: ready for prime time? Circulation. 2003;107(25):3243-3247.
3. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: functional markers. Circulation. 2004;109(25) (suppl 4):IV31-IV46.
4. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87(10):840-844.
5. Assmann G, Gotto AM Jr. HDL Cholesterol and protective factors in atherosclerosis. Circulation. 2004;109((23)(suppl 3):III8-III14.
6. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340(2):115-126.
7. Spady DK. Reverse cholesterol transport and atherosclerosis regression. Circulation. 1999;100(6):576-578.
8. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115(2):243-253.
9. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96(6):2882-2891.
10. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein.[published correction appears in FEBS Lett. 1991;292(1-2):307]. FEBS Lett. 1991;286(1-2):152-154.
11. Mackness B, Mackness MI, Durrington, et al. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest. 2000;30(1):4-10.
12. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res. 2006 Nov;47(11):2492-2502. Epub 2006 Aug 16.
13. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52(3):598-608.
14. Rodriguez-Esparragon F, Rodriguez-Perez JC, Hernandez-Trujillo Y, et al. Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: genotype-phenotype correlations. Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):854-860. Epub 2005 Jan 27.
15. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 1995;96(6):3005-3008.
16. Zama T, Murata M, Matsubara Y, et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol. 1997;17(12):3565-3569.
17. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 1997;17(6):1067-1073.
18. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 2004;363(9410):689-695.
19. Antikainen M, Murtomaki S, Syvanne M, et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest. 1996;98(4):883-885.
20. Herrmann SM, Blanc H, Poirier O, et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis. 1996;126(2):299-303.
21. Bauters C, Amant C, Boulier A, et al. Paraoxonase polymorphism (Gln192Arg) as a determinant of the response of human coronary arteries to serotonin. Circulation. 2000;101(7):740-743.
22. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(suppl 1):5S-20S.
23. Lavi S, Prasad A, Yang EH, et al. Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation. 2007 May 22;115(20):2621-2627. Epub 2007 May 7.
24. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101(9):948-954.
25. Hasdai D, Gibbons RJ, Holmes DR Jr, Higano ST, Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation. 1997;96(10):3390-3395.
26. Al Suwaidi J, Higano ST, Holmes DR Jr, Rihal CS, Lerman A. Measuring maximal percent area stenosis poststent placement with intracoronary Doppler and the continuity equation and correlation with intracoronary ultrasound and angiography. Am J Cardiol. 1999;84(6):650-654.
27. Svatikova A, Wolk R, Lerman LO, et al. Oxidative stress in obstructive sleep apnoea. Eur Heart J. 2005 Nov;26(22):2435-2439. Epub 2005 Aug 16.
28. Nagan N, O'Kane DJ. Validation of a single nucleotide polymorphism genotyping assay for the human serum paraoxonase gene using electronically active customized microarrays. Clin Biochem. 2001;34(7):589-592.
29. Peterson SE, Chen LS, Lagerstedt SA, et al. Luminex based method for multiplex analysis of inflammatory marker gene polymorphisms. Paper presented at: Association for Molecular Pathology Annual Meeting; November 16-19, 2006; Orlando, FL.
30. Ranade K, Kirchgessner TG, Iakoubova OA, et al. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke. 2005 Nov;36(11):2346-2350. Epub 2005 Oct 20.
31. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998;423(1):57-60.
32. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting lowdensity lipoprotein against lipid peroxidation [letter]. Lancet. 1997;349(9055): 851-852.
33. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(4):473-480.
34. Marathe GK, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem. 2003 Feb 7;278(6): 3937-3947. Epub 2002 Dec 3.
35. Connelly PW, Draganov D, Maguire GF. Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite. Free Radic Biol Med. 2005;38:164-174.
36. Kriska T, Marathe GK, Schmidt JC, McIntyre TM, Girotti AW. Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides. J Biol Chem. 2007 Jan 5;282(1):100-108. Epub 2006 Nov 6.
37. Imai Y, Morita H, Kurihara H, et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis. 2000;149(2):435-442.
38. Wang X, Fan Z, Huang J, et al. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol. 2003;23(2):328-334.
39. Lembo G, De Luca N, Battagli C, et al. A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke. 2001;32(3):735-740.
40. Jarvik GP, Hatsukami TS, Carlson C, et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1465-1471. Epub 2003 Jun 12.
41. Lusis AJ, Fogelman AM, Fonarow GC. Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation. 2004;110(13):1868-1873.
42. Manolio TA, Boerwinkle E, O'Donnell CJ, Wilson AF. Genetics of ultrasonographic carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1567-1577. Epub 2004 Jul 15.
43. Stulak JM, Lerman A, Porcel MR, et al. Renal vascular function in hypercholesterolemia is preserved by chronic antioxidant supplementation. J Am Soc Nephrol. 2001;12(9):1882-1891.
44. Pasqualini L, Cortese C, Marchesi S, et al. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis. 2005;183(2):349-354.
45. Srinivasan SR, Li S, Chen W, et al. Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community: the Bogalusa Heart Study. Atherosclerosis. 2004;177(1):167-174.
46. Yamane T, Matsumoto T, Nakae I, et al. Impact of paraoxonase polymorphism (Q192R) on endothelial function in intact coronary circulation. Hypertens Res. 2006;29(6):417-422.
47. Kuremoto K, Watanabe Y, Ohmura H, et al. R/R genotype of human paraoxonase (PON1) is more protective against lipoprotein oxidation and coronary artery disease in Japanese subjects. J Atheroscler Thromb. 2003;10(2):85-92.
48. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117(3):746-756.
49. Li D, Yang B, Mehta JL. Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am J Physiol. 1998; 275(2, pt 2):H568-H576.
50. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med. 2004;37(9):1304-1316.
51. Mathew JP, Podgoreanu MV, Grocott HP, et al, PEGASUS Investigative Team. Genetic variants in P-selectin and C-reactive protein influence susceptibility to cognitive decline after cardiac surgery. J Am Coll Cardiol. 2007 May 15;49(19):1934-1942. Epub 2007 Apr 30.